Enanta Pharmaceuticals, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Enanta Pharmaceuticals is in Stage 4, the downtrend phase, now in week 5 (since Sep 21, 2026). It closed at $11.62, 31.0% below its 52-week high and below its 200-day average, which is falling.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. More about the company

$11.62

+2.74% today

$338M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ENTA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 21w

S4 24w

S2 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 21w → S1 11w → S2 7w → S3 10w → S2 7w → S3 2w → S4 24w → S1 6w → S4 7w → S1 7w → S2 31w → S3 6w → S2 7w → S3 6w → S4 4w → S1 4w → S4 5w current

Total tracked: 165 weeks across 17 stage runs.

ENTA among Biotechnology166th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…166	ENTAEnanta Pharmaceuticals, Inc.	Stage 4 · wk 5	59	−2.8%

vs 52W High

-31.0%

$10.47 lo$16.85 hi

31.0% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-12.3%

200 DMA: $13.25 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.79x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-2.8%

-9.1%

-13.0%

YTD

-19.4%

+5.5%

Scan Membership

Breakout Watch

Latest: 2024-07-23

7 appearances in last 60 days. First seen: 2019-03-22.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.79x

2026-10-21S4

Wk 5 · Vol 0.49x

2026-10-20S4

Wk 5 · Vol 0.65x

2026-10-19S4

Wk 5 · Vol 1.17x

2026-10-16S4

Wk 4 · Vol 0.86x

2026-10-15S4

Wk 4 · Vol 0.71x

2026-10-14S4

Wk 4 · Vol 0.90x

2026-10-13S4

Wk 4 · Vol 0.69x

2026-10-12S4

Wk 4 · Vol 0.49x

2026-10-09S4

Wk 3 · Vol 0.72x

2026-10-08S4

Wk 3 · Vol 1.14x

2026-10-07S4

Wk 3 · Vol 0.77x

Moving averages & range

50 DMA

$12.73

200 DMA

$13.25

52W High

$16.85

52W Low

$10.47

5D Low

$11.10

Resistance levels (recent highs)

20d High

$13.18

60d High

$14.15

120d High

$15.46

250d High

$16.85

Next resistance

+13.4%

to 20d High

ROE

-70.1%

Profit margin -96.9%

Dividend Yield

0.00%

P/B 3.3

Enanta Pharmaceuticals: quick answers

What stage is Enanta Pharmaceuticals in?

As of Oct 22, 2026, Enanta Pharmaceuticals (ENTA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 21, 2026 and is in week 5. What the four stages mean

Is Enanta Pharmaceuticals in an uptrend?

No. Enanta Pharmaceuticals is in a Stage 4 downtrend. It trades 12.3% below its 200-day average, which is falling.

How far is Enanta Pharmaceuticals from its 52-week high?

Enanta Pharmaceuticals closed at $11.62 on Oct 22, 2026, 31.0% below its 52-week high of $16.85. Its 52-week low is $10.47.

How has Enanta Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Enanta Pharmaceuticals is up 5.5% over the past year and down 19.4% so far in 2026.

Which sector and industry is Enanta Pharmaceuticals in?

Enanta Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.